| Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. | |
| | |
MedLine Citation:
|
PMID: 20181806 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Disturbed apolipoprotein (apo) C-III metabolism in obese subjects may account for hypertriglyceridemia and increased risk of cardiovascular disease. Atorvastatin and fish oils decrease plasma triglycerides and VLDL concentrations, but the underlying mechanisms are not fully understood. OBJECTIVE: We studied the independent and combined effects of atorvastatin and fish oils on the metabolism of VLDL apo C-III in obese men. DESIGN: We carried out a 6-wk randomized, placebo-controlled, 2 x 2 factorial intervention study of atorvastatin (40 mg/d) and fish oils (4 g/d) on VLDL apo C-III kinetics in the postabsorptive state in 39 abdominally obese men using intravenous administration of d(3)-leucine. VLDL apo C-III isotopic enrichments were measured by using gas chromatography-mass spectrometry with kinetic parameters derived by using a multicompartmental model. RESULTS: Atorvastatin significantly (P < 0.05, main effect) increased the VLDL apo C-III fractional catabolic rate (+0.06 +/- 0.003 pools/d) without significantly altering its production rate (-0.14 +/- 0.18 mg . kg(-1) . d(-1)), accounting for a significant reduction in plasma VLDL apo C-III pool size (-44 +/- 17 mg/L). Fish-oil supplementation significantly decreased plasma triglycerides but did not significantly alter plasma VLDL apo C-III concentrations or kinetic parameters. Combination treatment provided no additional effect on VLDL apo C-III concentrations or kinetics compared with atorvastatin alone. CONCLUSIONS: In obesity, the triglyceride-lowering effect of atorvastatin, but not fish oils, is associated with increased VLDL apo C-III fractional catabolism and hence lower VLDL apo C-III concentrations. Combination treatment provided no significant additional improvement in VLDL apo C-III metabolism compared with atorvastatin alone. |
| | |
Authors:
|
Dick C Chan; Minh N Nguyen; Gerald F Watts; Esther Mm Ooi; P Hugh R Barrett |
Related Documents
:
|
15356086 - The influence of lipoprotein lipase gene variation on postprandial lipoprotein metabolism. 15675896 - Haemodynamically significant plaque formation and regional endothelial dysfunction in c... 7324936 - Plasma apoprotein and lipid patterns in newborns: influence of nutritional factors. 7772076 - High density lipoprotein metabolism is altered by dietary cholesterol but not fat satur... 6801956 - Effect of acute zinc deprivation on plasma zinc and platelet aggregation in adult males. 16553266 - Measurement of broiler litter production rates and nutrient content using recycled litter. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-02-24 |
Journal Detail:
|
Title: The American journal of clinical nutrition Volume: 91 ISSN: 1938-3207 ISO Abbreviation: Am. J. Clin. Nutr. Publication Date: 2010 Apr |
Date Detail:
|
Created Date: 2010-03-22 Completed Date: 2010-04-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0376027 Medline TA: Am J Clin Nutr Country: United States |
Other Details:
|
Languages: eng Pagination: 900-6 Citation Subset: AIM; IM |
Affiliation:
|
Metabolic Research Centre School of MedicinePharmacology Royal Perth Hospital University of Western Australia Perth Western Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anticholesteremic Agents / pharmacology*, therapeutic use Apolipoprotein C-III / blood, metabolism* Cholesterol, VLDL / blood* Dietary Supplements Double-Blind Method Drug Therapy, Combination Fatty Acids, Omega-3 / pharmacology*, therapeutic use Heptanoic Acids / pharmacology*, therapeutic use Humans Male Middle Aged Obesity, Abdominal / blood, drug therapy* Pyrroles / pharmacology*, therapeutic use Triglycerides / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Apolipoprotein C-III; 0/Cholesterol, VLDL; 0/Fatty Acids, Omega-3; 0/Heptanoic Acids; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Perceived Risk of Amputation, Emotions, and Foot Self-care Among Adults With Type 2 Diabetes.
Next Document: Review of muscle wasting associated with chronic kidney disease.